Author:
Torrisi Rosalba,Rota Selene,Losurdo Agnese,Zuradelli Monica,Masci Giovanna,Santoro Armando
Reference59 articles.
1. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database;Anderson;Breast Cancer Res. Treat.,2002
2. Htpps://www.nccn.org/professionals/physician/_gls/pdf/breast.
3. Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors;Bajetta;Ann. Oncol.,2000
4. Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR + ) breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy. Proc ASCO 2014;Bellet;J. Clin. Oncol. Abs.,2016
5. Patient-reported outcomes with adjuvant exemestaneversus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials;Bernhard;Lancet Oncol.,2015
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献